T1	Premise 45 144	A 58-year-old man comes for a scheduled check-up for type 2 diabetes mellitus diagnosed 6 years ago
T2	Premise 146 260	He has a personal history of hypertension, dyslipidemia, ischemic heart disease and pancreatitis of biliary origin
T3	Premise 262 341	His medication includes lisinopril, metoprolol, metformin, ASA and atorvastatin
T4	Premise 343 413	Physical examination showed blood pressure 151/93 mmHg, BMI 27.1 kg/m2
T5	Premise 415 442	Glycated hemoglobin is 8.3%
T6	Claim 522 534	Empaglifozin
T7	Claim 539 548	Glipizide
T8	Claim 553 561	Acarbose
T9	Claim 566 577	Sitagliptin
T10	Premise 604 658	Patient with obesity, hypertension and increased HbA1C
T11	Claim 660 773	In recent studies, Empaglifozin, a highly selective inhibitor of SGLT210, significantly reduces AT, HbA1C and BMI
R1	Support Ent1:T10 Ent2:T11	
T12	Treatment 679 691	Empaglifozin
R2	Support Ent1:T11 Ent2:T6	
T13	Claim 775 813	Glipizide is of the sulfonylurea group
T14	Claim 815 871	Its use should be avoided in patients with heart disease
R3	Support Ent1:T13 Ent2:T14	
R4	Attack Ent1:T14 Ent2:T7	
T15	Claim 873 949	Acarbose can interact with beta-blockers, such as those taken by our patient
T16	Claim 951 1013	Sitagliptin has been shown to decrease HbA1C but not HT or BMI
R5	Attack Ent1:T16 Ent2:T9	
R6	Support Ent1:T3 Ent2:T15	
R7	Attack Ent1:T15 Ent2:T8	
T17	Marker 996 999	but
T18	Treatment 522 534	Empaglifozin
T19	Treatment 539 548	Glipizide
T20	Treatment 553 561	Acarbose
T21	Treatment 566 577	Sitagliptin
T22	Treatment 775 784	Glipizide
T23	Treatment 873 881	Acarbose
T24	Treatment 951 962	Sitagliptin
